Oculis Secures $284.6M to Accelerate Groundbreaking Eye Care Innovations

Oculis, a pioneering global biopharmaceutical leader headquartered in Switzerland with key operations in the U.S. and Iceland, is proud to announce that it has successfully raised $284,600,000 in its latest funding round. This impressive capital infusion underscores the confidence that leading international healthcare investors have in Oculis' mission to save sight and improve eye care worldwide. The funds will be dedicated to advancing the company’s highly differentiated pipeline of innovative product candidates aimed at addressing some of the most critical unmet needs in eye care. Among these candidates is OCS-01, a topical eye drop that shows significant promise in the treatment of diabetic macular edema (DME), as well as in managing inflammation and pain following cataract surgery. In addition, the funding will further support the development of OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop designed for patients suffering from dry eye disease (DED) and non-infectious anterior uveitis. The investment will also accelerate progress on OCS-05, a neuroprotective candidate developed for acute optic neuritis (AON), potentially offering a transformative treatment option for patients facing vision loss. As Oculis continues to push the boundaries of medical science with its innovative treatments, this new funding will enable the company to expand clinical trials, enhance research capabilities, and ultimately bring these promising therapies to market. Oculis is led by an experienced management team with a track record of success, and this latest funding milestone marks a significant step forward in its ongoing commitment to improving patient health and quality of life globally. For more information about Oculis and its groundbreaking work, please visit www.oculis.com.